Banking Recap

Zentalis Pharmaceuticals, Inc. Prices Equity Offering for $95.5M

This transaction is a follow-on common stock offering by Zentalis Pharmaceuticals, Inc. (ticker ZNTL), a healthcare sector company. The offering falls under the equity capital markets (ECM) product group and carries a disclosed value of $95,450,000. The deal is currently in pending regulatory status.

Aug 14, 2026·SEC EDGAR (424B5)·pending regulatory·follow-on common stock offering

Deal value

This summary is sourced from an SEC EDGAR Form 424B5 filed and published on August 14, 2026.

The offering involved a syndicate of financial advisors in differentiated roles, all on the issuer side. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are each named as joint bookrunners in a lead capacity, per the source sentence listing the joint bookrunners as TD Cowen, Guggenheim Securities, and Oppenheimer & Co. H.C. Wainwright & Co. served in the distinct role of passive bookrunner, a non-lead capacity, while Rodman & Renshaw LLC served simply as manager, also non-lead.

No legal advisors are identified in the facts block for this transaction.

As a follow-on common stock offering, this transaction involves the sale of additional shares by an already-public issuer, but the facts block does not disclose the number of shares offered, the offering price per share, or any underwriters' over-allotment option terms.

Several material facts remain undisclosed. No legal advisors are named for the issuer or the underwriting syndicate. No expected closing date is given beyond the filing date, and no detail is provided on share count, price per share, or use of proceeds.